Dr. Gregory Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Dr. Verdine coined the phrase “drugging the undruggable” to describe his life mission. LifeMine is the brainchild of Dr. Verdine, who as a venture partner of WuXi Healthcare Ventures, led the founding team that brought the company from concept to reality. In his role as President, CEO and CSO of LifeMine, Dr. Verdine is leading the company through its ramp-up and march toward the clinic.
Dr. Verdine is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving Professor at Harvard University and Harvard Medical School, he made seminal contributions to understanding mechanisms of DNA repair and epigenetic DNA methylation and he invented a new drug modality called stapled peptides. As an entrepreneur, Dr. Verdine has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs.
Dr. Verdine has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and FOG, Dr. Verdine took a role in managing these companies as their president, chief executive officer and chief scientific officer.
Dr. Verdine earned his Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.